Colistimethate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Colistimethate: From Gram-Negative Bacterial Infections to Osteoarthritis
One-Sentence Summary
Colistimethate (colistin/polymyxin E prodrug) is a cationic polypeptide antibiotic historically used against multidrug-resistant Gram-negative bacterial infections. The TxGNN model predicts it may be effective for Osteoarthritis, but this prediction is currently supported by 0 clinical trials and 0 publications — it rests entirely on knowledge-graph embedding similarity, with no mechanistic or clinical corroboration found.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multidrug-resistant Gram-negative bacterial infections (based on known pharmacological classification; no India/Taiwan regulatory license record available) |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 97.78% |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this candidate ([Data Gap] in the evidence pack). Based on known pharmacological information, colistimethate is a prodrug of colistin, a cationic polypeptide antibiotic that binds lipopolysaccharide (LPS) on the outer membrane of Gram-negative bacteria and disrupts membrane integrity to achieve bactericidal effect. This is a purely antibacterial mechanism.
Osteoarthritis pathology is driven by cartilage degeneration and mechanical wear, with no established antimicrobial or LPS-related component in its core disease process. The evidence pack’s own repurposing rationale for this candidate explicitly states there is no known molecular connection between colistimethate’s mechanism and osteoarthritis, and that the TxGNN score reflects only knowledge-graph embedding similarity rather than a validated biological link.
Given the absence of MOA confirmation, clinical trials, and literature, this prediction should be treated as a hypothesis-generation signal only, not as evidence of therapeutic plausibility. The same caveat applies to the other 9 predicted indications in this evidence pack (rheumatoid arthritis, osteoarthritis susceptibility, gout, pseudoachondroplasia, hepatic porphyria, brachyolmia, primitive portal vein thrombosis, hepatopulmonary syndrome, hepatoportal sclerosis) — all are scored L5/S0 with no corroborating mechanistic, clinical, or literature evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Drug Interactions (33 total interactions on record; major examples below):
- Major risk (nephrotoxicity/neurotoxicity synergy): Kanamycin, Neomycin, Streptomycin (concurrent aminoglycosides); Deferasirox; iodinated contrast media — Diatrizoate, Iodipamide, Iodixanol, Iohexol, Iopamidol, Iopromide, Iothalamic acid, Ioversol, Ioxilan (increased nephrotoxicity risk with contrast agents)
- Moderate risk: Mesalazine, Balsalazide, Olsalazine, Sulfasalazine (aminosalicylates), Vancomycin, Exenatide, Picosulfuric acid
Detailed key warnings and contraindications (e.g., TFDA/local label warnings) are not currently available in this evidence pack — this is flagged as a Blocking data gap (DG001) that prevents completion of the S1 safety pre-screen.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate carries only an L5 (model-prediction-only) evidence level with an S0 decision stage — there are zero supporting clinical trials or publications, and the candidate’s own mechanistic rationale explicitly finds no biological connection between colistimethate’s antibacterial mode of action and osteoarthritis. A Blocking-severity data gap (missing label warnings/contraindications) also prevents any safety pre-screen from being completed.
To proceed, the following is needed:
- TFDA/local product label (warnings, contraindications) — required before any S1 safety screening (DG001, Blocking)
- Confirmed mechanism of action data via DrugBank or primary literature (DG002, High)
- At minimum, preclinical/mechanistic studies linking colistin-class antibiotics to osteoarthritis pathology before further investment
- Ongoing monitoring for any emerging clinical trial or literature evidence for this drug-disease pair
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.